Does Benign Prostatic Tissue Contribute to Measurable PSA Levels After Radical Prostatectomy?

Urology

Volumn 74, Issue 1, 2009, Pages 167-170

  Godoy, Guilherme ^a   Tareen, Basir U ^a   Lepor, Herbert ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 67649210290     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.07.067     Document Type: Article

References (27)

1. Ponthieu A., Delgrande J., and Ivaldi A. Perioperative biopsy of the sub-apical urethra during prostatectomy for cancer. Prog Urol 6 (1996) 250-256
2. Paul R., Hoppmann M., van Randenborgh H., et al. Residual benign prostatic glands at the urethrovesical anastomosis after radical retropubic prostatectomy: Prediction and impact on disease outcome. Eur Urol 46 (2004) 321-326
3. Shah O., Melamed J., and Lepor H. Analysis of apical soft tissue margins during radical retropubic prostatectomy. J Urol 165 (2001) 1943-1949
4. Tongco W.P., Wehner M.S., and Basler J.W. Does urethral-sparing prostatectomy risk residual prostate cancer?. Urology 57 (2001) 495-498
5. Lepor H., Chan S., and Melamed J. The role of bladder neck biopsy in men undergoing radical retropubic prostatectomy with preservation of the bladder neck. J Urol 160 (1998) 2435-2439
6. Shah R., Bassily N., Wei J., et al. Benign prostatic glands at surgical margins of radical prostatectomy specimens: Frequency and associated risk factors. Urology 56 (2000) 721-725
7. Wood Jr. D.P., Peretsman S.J., and Seay T.M. Incidence of benign and malignant prostate tissue in biopsies of the bladder neck after a radical prostatectomy. J Urol 154 (1995) 1443-1446
8. Djavan B., Milani S., and Fong Y.K. Benign positive margins after radical prostatectomy means a poor prognosis-Pro. Urology 65 (2005) 218-220
9. Djavan B., Sesterhann I., Hruby S., et al. Benign prostatic glands in the surgical margin of radical prostatectomies: Redefining PSA nadir. J Urol 163 (2000) A624
10. Fowler Jr. J.E., Brooks J., Pandey P., et al. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 153 (1995) 1011-1014
11. Lepor H. Radical retropubic prostatectomy. Urol Clin North Am 28 (2001) 509-519 viii
12. Bostwick D.G., and Foster C.S. Pathology of the Prostate (1998), WB Saunders, Philadelphia 72
13. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
14. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
15. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277 (1997) 1445-1451
16. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58 (2001) 843-848
17. Makarov D.V., Trock B.J., Humphreys E.B., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007) 1095-1101
18. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166 (2001) 2185-2188
19. Lee A.K., Schultz D., Renshaw A.A., et al. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys 49 (2001) 673-677
20. Lieberfarb M.E., Schultz D., Whittington R., et al. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys 53 (2002) 898-903
21. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005) 7005-7012
22. Dillioglugil O., Leibman B.D., Kattan M.W., et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 50 (1997) 93-99
23. Eastham J.A., Kuroiwa K., Ohori M., et al. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology 70 (2007) 965-969
24. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am 24 (1997) 395-406
25. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007) 540-545
26. Perlmutter M.A., and Lepor H. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy. Urology 71 (2008) 501-505
27. Lepor H., Williford W.O., Barry M.J., et al., Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335 (1996) 533-539